CompletedNot Applicable

Acamprosate: Genes Associated With Response

United States485 participantsStarted 2008-05

Plain-language summary

In 2004, acamprosate was approved in the U.S. for abstinence maintenance, by decreasing craving, in alcoholic patients who have undergone detoxification. while a new anti-craving drug was encouraging, only 36.1% of the subjects treated with acamprosate remained abstinent for 6 months. Having the ability to identify treatment responsive individuals would have a major impact on the use of acamprosate.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or females, Age 18-80.

Exclusion criteria

✕. Prior enrollment in the IRB approved protocol "Developing a DNA Repository for Genomic Studies of Addiction: A Pilot Study".
✕. Inability to provide informed consent.
✕. Inability to speak English.
✕. History of hypersensitivity or allergic reaction to acamprosate.
✕. Moderate to severe renal impairment, as determined by a creatinine level \> 1.5 mg/dL.
✕. Diagnosis of primary biliary cirrhosis, chronic active hepatitis, and drug-induced hepatic insufficiency, as noted in the medical record.
✕. Women who are pregnant, lactating, or are planning to become pregnant during the next year.
✕. Any unstable active medical or additional psychiatric condition as determined by the investigator.

What they're measuring

Aim 1: To determine the relationship between genetically determined variation in the NMDA receptor and treatment response to acamprosate.

Timeframe: 6 months

Trial details

NCT IDNCT00662571

SponsorMayo Clinic

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2013-02

View on ClinicalTrials.gov More Alcoholism trials